Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 439 matching trials from the live ClinicalTrials.gov search.
Completed No phase listed Observational Accepts healthy volunteers

Study of Generalized Movements for Early Prediction of Cerebral Palsy

NCT00749008
Conditions
Cerebral Palsy, Prematurity
Interventions
Not listed
Lead sponsor
Charles R. Neal,
Other
Eligibility
Up to 2 Months
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Honolulu, Hawaii
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam
Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 23 more
Conditions
Dravet Syndrome
Interventions
Clobazam, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
1 Year to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
8
States / cities
Los Angeles, California • Orlando, Florida • Rochester, Minnesota + 4 more
Conditions
Charcot-Marie-Tooth Disease, Charcot-Marie-Tooth, Charcot-Marie-Tooth Disease, Type IA, Charcot-Marie-Tooth Disease Type 2A, Charcot-Marie-Tooth Disease Type 2, Charcot-Marie-Tooth Disease, Type 2C, Charcot-Marie-Tooth Disease Type 2A2B, Charcot-Marie-Tooth Disease Type 2B2, Charcot-Marie-Tooth Disease Type 2A1, Charcot-Marie-Tooth Disease Type 4B1, Charcot-Marie-Tooth Disease, Type IB, Charcot-Marie-Tooth Disease Type 2B1, Charcot-Marie-Tooth Disease Type 2U (Diagnosis), Charcot-Marie-Tooth Disease Type 4A, Charcot-Marie-Tooth Disease, Type 4A, Axonal Form, Charcot-Marie-Tooth Disease Type 2A2A, Charcot-Marie-Tooth Disease Type 2S (Disorder), Charcot-Marie-Tooth Disease and Deafness, Charcot-Marie-Tooth Disease Type 4B2, Charcot-Marie-Tooth Disease Type 4H, Charcot-Marie-Tooth Disease Type 1F, Charcot-Marie-Tooth Disease Type 4C, Charcot-Marie-Tooth Disease Type 4E, Charcot-Marie-Tooth Disease Type 1D, Charcot-Marie-Tooth Disease Type 2Q (Diagnosis), Charcot-Marie-Tooth Disease Type 2A2, Charcot-Marie-Tooth Disease Type 2N (Diagnosis), Charcot-Marie-Tooth Disease Type 2B5, Charcot-Marie-Tooth Disease Type 2D, Charcot-Marie-Tooth Disease Type 4D, Charcot-Marie-Tooth Disease Type 2K, Charcot-Marie-Tooth Disease Type 2L (Diagnosis), Charcot-Marie-Tooth Disease Type 2T, Charcot-Marie-Tooth Disease Type 2I, Charcot-Marie-Tooth Disease Type 2J, Charcot-Marie-Tooth Disease Type 2E, Charcot-Marie-Tooth Disease Type 2G, Charcot-Marie-Tooth Disease Type 1C, Charcot-Marie-Tooth Disease Type 2R, Charcot-Marie-Tooth Disease Type 2O (Diagnosis), Charcot-Marie-Tooth Disease Type 2M, Charcot-Marie-Tooth Disease Type 2P, Charcot-Marie-Tooth Disease Type 2Y, Charcot-Marie-Tooth Disease Type 4F (Diagnosis), Charcot-Marie-Tooth Disease Type 4B3, Charcot-Marie-Tooth Disease Type 2H, HNPP, X-Linked Charcot-Marie-Tooth Disease, Charcot Marie Tooth Disease (CMT)
Interventions
Not listed
Lead sponsor
Hereditary Neuropathy Foundation
Government
Eligibility
Not listed
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2029
U.S. locations
1
States / cities
New York, New York
Conditions
Generalized Myasthenia Gravis
Interventions
Ravulizumab, Placebo
Biological · Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
49
States / cities
Phoenix, Arizona • Irvine, California • Loma Linda, California + 43 more
Conditions
Dravet Syndrome
Interventions
Clemizole HCl, Placebo
Drug
Lead sponsor
Epygenix
Industry
Eligibility
2 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
31
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 27 more
Enrolling by invitation Phase 3 Interventional Accepts healthy volunteers

GA + ESP vs. SA + ESP in Lumbar Decompression Surgeries

NCT05444751
Conditions
Lumbar Disc Herniation, Lumbar Disc Disease, Lumbar Radiculopathy
Interventions
General anesthetic, SA + ESP
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Terminated No phase listed Observational Accepts healthy volunteers

Brain Changes in Blepharospasm

NCT00487383
Conditions
Dystonia, Focal Dystonia, Cerebellar Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Infantile Spasm
Interventions
Cannabidiol Oral Solution, Placebo, Vigabatrin
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
1 Month to 24 Months
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Miami, Florida • Royal Oak, Michigan • Akron, Ohio + 2 more
Conditions
Generalized Myasthenia Gravis
Interventions
Whole-body Electrical Muscle Stimulation Exercise
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Fairway, Kansas • Columbia, Missouri
Completed Phase 2 Interventional Results available

Clobazam in Subjects With Lennox-Gastaut Syndrome

NCT00162981
Conditions
Epilepsy, Epilepsy, Generalized, Seizures
Interventions
Clobazam Low Dose, Clobazam High Dose
Drug
Lead sponsor
Lundbeck LLC
Industry
Eligibility
2 Years to 30 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Active, not recruiting Phase 2 Interventional

Use of CBD in the Treatment of Anxiety

NCT06672666
Conditions
Anxiety, Generalized Anxiety Disorder, Sleep Problems
Interventions
Hemp Derived Cannabidiol Extract, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study

NCT00088452
Conditions
Childhood Absence Epilepsy, Petit Mal Epilepsy, Epilepsy, Seizures
Interventions
Ethosuximide, Lamotrigine, Valproic acid
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
30 Months to 13 Years
Enrollment
453 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2016
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 28 more
Conditions
Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
Interventions
TAK-935, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 12 more
Conditions
Rare Diseases, Autism or Autistic Traits, Development Delay, SYT-SSX Fusion Protein Expression, Sleep Disorder, Epilepsy, Generalized, Motor Delay
Interventions
Brain Magnetic Resonance Imaging (MRI), Whole Genome Sequencing, Induced Pluripotential Stem Cells
Diagnostic Test · Genetic · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
0 Years to 99 Years
Enrollment
50 participants
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
No Longer Available No phase listed Expanded access

Stiripentol in Dravet Syndrome

NCT01533506
Conditions
Dravet Syndrome
Interventions
stiripentol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
11 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Advanced Parkinson's Disease
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Boca Raton, Florida • Gainesville, Florida + 16 more
Conditions
Generalized Myasthenia Gravis
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
2 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Charlotte, North Carolina • Denton, Texas • Charlottesville, Virginia
Conditions
Myasthenia Gravis, Generalized
Interventions
Descartes-08
Drug
Lead sponsor
Cartesian Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
14
States / cities
Carlsbad, California • Irvine, California • Aurora, Colorado + 11 more
Conditions
Myasthenia Gravis
Interventions
Nipocalimab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 8 more
Conditions
Generalized Myasthenia Gravis
Interventions
YTB323
Genetic
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Orange, California • Winston-Salem, North Carolina • Philadelphia, Pennsylvania + 1 more
Conditions
Autoimmune Encephalitis (AE)
Interventions
Efgartigimod PH20 (ARGX-113) SC, Placebo PH20 SC
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
12 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Tucson, Arizona • Sherman, Texas
Conditions
Delirium
Interventions
Ramelteon, Citicoline
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Generalized Myasthenia Gravis
Interventions
Zilucoplan
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
New Haven, Connecticut • Tampa, Florida • Columbia, Missouri + 4 more